Paper No. ____ Filed: April 25, 2016

BEFORE THE PATENT TRIAL AND APPEAL BOARD
MYLAN PHARMACEUTICALS INC. and MYLAN LABORATORIES LIMITED, Petitioners
v. BAXTER INTERNATIONAL INC. and BAXTER HEALTHCARE S. A. Patent Owners

UNITED STATES PATENT AND TRADEMARK OFFICE

JOINT MOTION TO TERMINATE PROCEEDING PURSUANT TO 35 U.S.C. § 317

Case IPR2016-00217 Patent No. 6,310,094



I. INTRODUCTION

Pursuant to 35 U.S.C. § 317(a), Petitioners Mylan Pharmaceuticals Inc. and Mylan Laboratories Limited ("Petitioners") and Baxter International, Inc. and Baxter Healthcare S. A. ("Patent Owners") (together, "the Parties") jointly request termination of the *inter partes* Review of U.S. Patent No. 6,310,094, Case No. IPR2016-00217. In accordance with 37 C.F.R. § 42.20(b), the Parties sought, and received, authorization from the Board to file this motion on April 25, 2016.

The Parties have settled their disputes. The Parties' settlement is memorialized in a Settlement Agreement, a true and correct copy of this agreement is filed as Exhibit 1026. The parties desire that the Settlement Agreement be maintained as business confidential information under 37 C.F.R. § 42.74(c) and a joint request to that effect is being filed concurrently herewith.

II. TERMINATION IS APPROPRIATE

Termination of this proceeding is proper because the IPR is in its early stages. The Board has not yet "decided the merits of the proceeding before the request for termination is filed." 35 U.S.C. § 317(a); 77 Fed. Reg. 48768 ("The Board expects that a proceeding will terminate after the filing of a settlement agreement, unless the Board has already decided the merits of the proceeding."). *See Oracle Corp. v. Community United IP, LLC*, Case No. CBM2013-00015, Paper No. 13 (PTAB Jul. 25, 2013) (citing Office Patent Trial Practice Guide, 77 Fed. Reg. 48756, 48768 (Aug. 14, 2012)).



Case No. IPR2016-00217 U.S. Patent No. 6,310,094

At this early point in the proceeding, no decision on institution has been issued by the Board. Thus, the Board has not yet decided the merits of the proceeding at the time this motion for termination is filed.

The litigation between the Parties related to this proceeding has also been settled.¹ And the Parties are unaware of any other matter before the USPTO that would be affected by the settlement and termination of this proceeding, and there are no other proceedings before the Board involving the '094 Patent.

For all these reasons, the Parties respectfully request the Board terminate this proceeding, Case No. IPR2016-00217.

Dated: April 25, 2016 Respectfully submitted,

/ Steven W. Parmelee /
Steven W. Parmelee
Registration No. 31,990
Wilson Sonsini Goodrich & Rosati
701 Fifth Avenue, Suite 5100
Seattle, WA 98104

Tel.: 206-883-2542

Email: sparmelee@wsgr.com

Attorneys for Petitioners

¹ Other litigations involving the '094 Patent are still pending, but do not involve the Petitioners.



2

/ James W. Hill /

James W. Hill Registration No. 46,396 Wilmer Cutler Pickering Hale and Dorr LLP 350 South Grand Avenue, Suite 2100 Los Angeles, CA 90071

Tel.: 213-443-5300

Email: James.Hill@wilmerhale.com

Attorneys for Patent Owners



LIST OF EXHIBITS

Exhibit No.	Description
1001	U.S. Patent No. 6,310,094 to Liu et al.
1002	Declaration of Robert J. Linhardt, Ph.D.
1003	Curriculum Vitae of Robert J. Linhardt, Ph.D.
1004	File history of 6,310,094 to Liu et al.
1005	Brevibloc [®] Injection. (1999). In <i>Physicians' Desk Reference</i> (53rd ed., 624-626). Montvale, NJ: PDR Network.
1006	Y.C. Lee et al., High-Performance Liquid Chromatographic Method for the Determination of Esmolol Hydrochloride. 73 J. Pharm. Sci. 1660 (1984)
1007	S. Turco and R. E. King, <i>Chapters 4 and 8</i> , STERILE DOSAGE FORMS: THEIR PREPARATION AND CLINICAL APPLICATION (3rd ed., 1987)
1008	U.S. Patent No. 5,129,894 to Sommermeyer et al.
1009	Brevibloc Injection Label, Center for Drug Evaluation and Research, 1988.
1010	L. Blanski et al., Esmolol, the first ultra-short-acting intravenous beta blocker for use in critically ill patients, 17 HEART LUNG 80 (1988)
1011	D.J. Pearce, <i>Brevibloc drug errors</i> , 43 CAN. J. ANESTH. 419 (1996)
1012	U.S. Patent No. 4,857,552 to Rosenberg et al.
1013	Chapters 36 and 84, Remington's 19 th Edition: The Science and Practice of Pharmacy. (A. Gennaro ed. 1995)
1014	D. M. Baaske et al., Stability of esmolol hydrochloride in intravenous solutions, 51 Am. J. HOSP. PHARM. 2693 (1994)
1015	P. Pittenger, <i>The Biologic Standardization of Local Anesthetics</i> With Special Reference to Effect of Sterilization on Solutions of Cocaine and Procaine, 12 J. Am. Pharm. Assoc. 229 (1923)
1016	J. B. Murray et al. Stability of Cocaine in Aqueous Solution 3 J. CLIN. PHARM. 1 (1978)
1017	J. T. Murphy et al., Preparation, Sterilization, and Preservation of Ophthalmic Solutions: Experimental Studies and a Practical



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

